eMurmur ID is an artificial intelligence-based solution that enables healthcare providers to detect and classify heart murmurs with expert-level accuracy
OTTAWA, May 14, 2019 /PRNewswire/ - eMurmur® today announced that its flagship "eMurmur ID" solution has received FDA clearance, enabling a new era in heart murmur detection. eMurmur ID is a mobile and cloud solution which operates in conjunction with a 3rd party electronic stethoscope. It uses advanced machine learning to identify and classify pathologic and innocent heart murmurs, the absence of a heart murmur, and S1, S2 heart sounds. The end-to-end solution is comprised of AI-based analytics, a mobile app, and a web portal (all HIPAA compliant). It supports the workflows of healthcare providers performing cardiac auscultation and has multiple applications including primary and specialty care, and corporate health.
"The eMurmur ID solution has the potential to disrupt medical care", said Dr. Derek Exner, Professor and Canada Research Chair in Cardiovascular Clinical Trials at the University of Calgary. "The evidence for its utility is solid and includes five studies on over 1000 patients, including blinded, multi-centre trials. This system has been shown to be accurate, informative, and easy-to-use. It provides healthcare professionals with a potent screening tool and method to confirm their clinical diagnoses, enhancing patient care."
"Receiving FDA clearance marks a significant milestone in our company's history, and I'm very excited to finally be able to take the eMurmur ID solution to market," said Andreas Schriefl, co-founder and CEO of eMurmur. "We believe that eMurmur ID has the potential to disrupt the status-quo of heart murmur screening and significantly reduce costs to healthcare systems worldwide."
"From a technology perspective, receiving FDA clearance requires solid clinical proof of the algorithm performance characteristics, as well as a quality and risk management system that ensures patient safety and compliance with stringent regulatory standards," said Andreas Reinisch, co-founder and CTO of eMurmur. "Through this process, our company has gained significant knowledge and expertise to facilitate and support future AI- based medical solutions."
About eMurmur
Founded in 2014 in Austria, eMurmur is a privately-held medical technology company specializing in Machine Learning for the analysis of data for medical applications. eMurmur also provides heart-auscultation educational solutions. The company is based in Ottawa, Canada and Graz, Austria. It does business under the name eMurmur.
For media inquiries, contact:Jolisa Masucol[email protected]www.emurmur.com
Advertisement
OTTAWA, May 14, 2019 /PRNewswire/ - eMurmur® today announced that its flagship "eMurmur ID" solution has received FDA clearance, enabling a new era in heart murmur detection. eMurmur ID is a mobile and cloud solution which operates in conjunction with a 3rd party electronic stethoscope. It uses advanced machine learning to identify and classify pathologic and innocent heart murmurs, the absence of a heart murmur, and S1, S2 heart sounds. The end-to-end solution is comprised of AI-based analytics, a mobile app, and a web portal (all HIPAA compliant). It supports the workflows of healthcare providers performing cardiac auscultation and has multiple applications including primary and specialty care, and corporate health.
Advertisement
"The eMurmur ID solution has the potential to disrupt medical care", said Dr. Derek Exner, Professor and Canada Research Chair in Cardiovascular Clinical Trials at the University of Calgary. "The evidence for its utility is solid and includes five studies on over 1000 patients, including blinded, multi-centre trials. This system has been shown to be accurate, informative, and easy-to-use. It provides healthcare professionals with a potent screening tool and method to confirm their clinical diagnoses, enhancing patient care."
"Receiving FDA clearance marks a significant milestone in our company's history, and I'm very excited to finally be able to take the eMurmur ID solution to market," said Andreas Schriefl, co-founder and CEO of eMurmur. "We believe that eMurmur ID has the potential to disrupt the status-quo of heart murmur screening and significantly reduce costs to healthcare systems worldwide."
"From a technology perspective, receiving FDA clearance requires solid clinical proof of the algorithm performance characteristics, as well as a quality and risk management system that ensures patient safety and compliance with stringent regulatory standards," said Andreas Reinisch, co-founder and CTO of eMurmur. "Through this process, our company has gained significant knowledge and expertise to facilitate and support future AI- based medical solutions."
About eMurmur
Founded in 2014 in Austria, eMurmur is a privately-held medical technology company specializing in Machine Learning for the analysis of data for medical applications. eMurmur also provides heart-auscultation educational solutions. The company is based in Ottawa, Canada and Graz, Austria. It does business under the name eMurmur.
For media inquiries, contact:Jolisa Masucol[email protected]www.emurmur.com
View original content:http://www.prnewswire.com/news-releases/fda-grants-clearance-for-a-heart-murmur-detection-solution-on-a-personal-mobile-device-300849822.html
SOURCE eMurmur
